P

PharmaResearch Co Ltd
KOSDAQ:214450

Watchlist Manager
PharmaResearch Co Ltd
KOSDAQ:214450
Watchlist
Price: 209 500 KRW -4.34% Market Closed
Market Cap: 2.2T KRW
Have any thoughts about
PharmaResearch Co Ltd?
Write Note

Balance Sheet

Balance Sheet Decomposition
PharmaResearch Co Ltd

Current Assets 312.1B
Cash & Short-Term Investments 189.4B
Receivables 53.9B
Other Current Assets 68.9B
Non-Current Assets 289.4B
Long-Term Investments 105.8B
PP&E 138.4B
Intangibles 32.1B
Other Non-Current Assets 13B
Current Liabilities 85.6B
Accounts Payable 10.2B
Accrued Liabilities 1.4B
Short-Term Debt 250m
Other Current Liabilities 73.8B
Non-Current Liabilities 35.1B
Long-Term Debt 1.9B
Other Non-Current Liabilities 33.2B

Balance Sheet
PharmaResearch Co Ltd

Rotate your device to view
Balance Sheet
Currency: KRW
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
9 890
14 864
17 634
16 990
21 096
19 738
26 715
41 674
72 931
67 245
Cash
0
1
2
6
0
2
5
3
8
67 245
Cash Equivalents
9 890
14 863
17 632
16 984
21 096
19 736
26 710
41 672
72 923
0
Short-Term Investments
13
108 181
92 349
70 622
54 301
49 292
52 552
115 123
111 412
93 053
Total Receivables
6 255
5 850
10 782
18 358
17 243
20 589
26 351
30 510
36 415
36 330
Accounts Receivables
4 610
5 725
10 689
15 310
16 028
20 225
22 890
27 928
33 202
31 812
Other Receivables
1 645
125
93
3 048
1 215
364
3 461
2 582
3 213
4 519
Inventory
2 197
4 783
5 445
5 119
12 294
13 928
20 781
17 342
24 453
50 232
Other Current Assets
659
538
259
1 247
836
926
1 005
2 142
2 134
9 604
Total Current Assets
19 014
134 214
126 468
112 335
105 769
104 473
127 404
206 792
247 345
256 465
PP&E Net
21 023
20 396
20 771
27 179
66 064
73 886
94 046
109 481
117 960
123 061
PP&E Gross
21 023
20 396
20 771
27 179
66 064
73 886
94 046
109 481
117 960
123 061
Accumulated Depreciation
1 402
2 442
3 773
5 021
7 778
12 166
15 677
21 839
26 837
34 079
Intangible Assets
1 583
1 647
2 289
2 284
31 980
29 806
26 811
26 025
24 017
20 323
Goodwill
0
0
1 918
1 036
13 738
13 738
12 492
16 764
13 810
11 652
Note Receivable
0
0
0
0
1 000
3 624
0
4 794
4 434
3 938
Long-Term Investments
2 471
12 905
27 652
45 048
37 150
40 552
54 395
58 268
59 361
112 777
Other Long-Term Assets
294
144
233
1 151
2 488
3 847
4 684
5 523
11 128
7 066
Other Assets
0
0
1 918
1 036
13 738
13 738
12 492
16 764
13 810
11 652
Total Assets
44 385
N/A
169 306
+281%
179 332
+6%
189 034
+5%
258 188
+37%
269 925
+5%
319 831
+18%
427 647
+34%
478 055
+12%
535 281
+12%
Liabilities
Accounts Payable
1 272
1 064
2 029
1 732
4 457
5 359
1 876
2 939
3 527
2 831
Accrued Liabilities
131
135
179
115
333
492
534
703
860
974
Short-Term Debt
2 500
0
0
0
0
0
15 000
15 800
15 550
400
Current Portion of Long-Term Debt
3 210
0
0
0
3 019
3 507
4 581
4 961
5 024
32 573
Other Current Liabilities
3 507
5 960
3 999
5 016
7 671
9 232
13 858
23 602
29 292
29 121
Total Current Liabilities
10 620
7 158
6 207
6 863
15 480
18 590
35 849
48 005
54 253
65 899
Long-Term Debt
8 997
5 401
0
0
17 343
17 435
12 829
44 850
46 194
1 301
Deferred Income Tax
0
0
114
0
6 061
5 404
4 746
4 514
3 741
2 794
Minority Interest
0
0
824
3 299
21 250
19 349
18 989
22 917
28 153
29 091
Other Liabilities
0
0
546
19
430
73
1 996
1 919
2 211
3 092
Total Liabilities
19 617
N/A
12 559
-36%
7 691
-39%
10 181
+32%
60 565
+495%
60 851
+0%
74 409
+22%
122 205
+64%
134 552
+10%
102 178
-24%
Equity
Common Stock
3 005
4 582
4 733
4 733
4 733
4 777
4 895
5 056
5 056
5 160
Retained Earnings
21 965
34 843
46 859
56 994
69 027
82 783
112 615
154 018
190 862
260 787
Additional Paid In Capital
0
116 629
121 893
121 893
122 113
124 366
131 120
150 127
155 297
172 641
Unrealized Security Profit/Loss
0
3
76
166
86
237
104
803
4 835
3 815
Treasury Stock
0
0
2 684
4 987
267
5 260
5 260
5 260
5 260
4 638
Other Equity
203
689
763
54
1 932
2 171
1 950
2 303
2 383
2 969
Total Equity
24 768
N/A
156 747
+533%
171 641
+10%
178 853
+4%
197 623
+10%
209 075
+6%
245 423
+17%
305 442
+24%
343 503
+12%
433 104
+26%
Total Liabilities & Equity
44 385
N/A
169 306
+281%
179 332
+6%
189 034
+5%
258 188
+37%
269 925
+5%
319 831
+18%
427 647
+34%
478 055
+12%
535 281
+12%
Shares Outstanding
Common Shares Outstanding
6
9
9
9
9
9
10
10
10
10
Preferred Shares Outstanding
1
0
0
0
0
0
0
0
0
0

See Also

Discover More